Annoviant develops TxGuard™, a patented regenerative tissue technology that utilizes patients' own cells to create biological prosthetic heart valves. This innovation addresses the clinical challenges of calcification, thrombosis, and degeneration, significantly reducing the need for repeat surgeries and associated healthcare costs.
Funding
$600K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current biological prosthetic heart valves face limitations including calcification, thrombosis, infection, and degeneration, leading to repeat surgeries and increased hospitalization costs, particularly for younger patients. These challenges result in suboptimal long-term outcomes and a diminished quality of life for individuals with life-threatening cardiovascular diseases.
Solution
Annoviant develops TxGuard™, a patented regenerative tissue technology that utilizes a patient's own cells to create biological prosthetic heart valves, addressing the clinical challenges of existing devices. TxGuard™ is designed to regenerate and heal with the patient, potentially eliminating the need for multiple re-interventions. This breakthrough innovation aims to improve long-term outcomes and quality of life for patients suffering from cardiovascular diseases and requiring soft tissue applications. The technology is being explored for cardiovascular, urology, gastro, graft, and wound applications.
Target Audience
The primary target audience includes cardiovascular surgeons, interventional cardiologists, and hospitals focused on providing advanced treatment options for patients with heart valve disease, as well as patients requiring soft tissue regeneration.
Features
- Regenerative properties allowing the tissue to heal and grow with the patient.
- Thrombo-resistant design to minimize the risk of blood clot formation.
- Calcification-resistant materials to prevent valve hardening and dysfunction.
- Pliable construction for improved flexibility and hemodynamic performance.
- Potential for use in cardiovascular, urology, gastro, graft, and wound applications.